Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report
Yu Zhang, Zhenling Chen, Jianying Li, Xuejing Wang, Yi Liu · 2024
Read Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report by Yu Zhang, Zhenling Chen, Jianying Li, Xuejing Wang, Yi Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11630917.txt.
Description
Yu Zhang and co-authors report a dangerous reaction to blood thinners during COVID-19 care, in a 2024 case report. COVID-19 clots veins readily, and heparin drugs are the standard defense. Rarely, heparin itself triggers an antibody attack that crashes platelet counts while spawning new clots, a paradox called heparin-induced thrombocytopenia.
The patient, an eighty-six-year-old man, was receiving nadroparin for a lung embolism when his platelets plunged and leg clots worsened. A standard scoring checklist rated the reaction likely. All heparin drugs stopped at once, and argatroban took over the anticoagulation. His platelet count then climbed back to normal. The authors warn clinicians to keep the reaction in mind whenever counts fall on heparin.
Catalog record
| CREATOR | Yu Zhang, Zhenling Chen, Jianying Li, Xuejing Wang, Yi Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |